INC-005 is under clinical development by HK inno.N and currently in Phase II for Helicobacter pylori Infections. According to GlobalData, Phase II drugs for Helicobacter pylori Infections have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INC-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INC-005 overview
IN-C005 is under development for the treatment of gastroesophageal reflux disease and helicobacter pylori infections. The drug candidate is an incrementally modified drug (IMD). It is administered through oral route.
HK inno.N overview
HK inno.N, a subsidiary of Kolmar Korea Co Ltd, is a manufacturer of active pharmaceutical ingredients and prescription drugs. Its product portfolio includes EPOKINE for the treatment of renal anemia, Leukokine to treat neutropenia, Calmtop for the treatment of colorectal cancer, Movealoxin, Cinezolid, Omapone a parenteral nutrition product, and Pemta an infusion solution. HK inno.N is headquartered in Seoul, South Korea.
For a complete picture of INC-005’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
